October 20, 1936 |
Long Island, New York
|Occupation||Chairman and CEO, BioCatalyst International|
Sheridan Gray Snyder OBE, LLB (born October 20, 1936), Sherry Snyder, is an entrepreneur and venture capitalist:6 in the biotechnology industry. He is the founder and CEO of Biocatalyst, but also a "serial entrepreneur", a founder of Genzyme and many other companies. Snyder, who was the University of Virginia's best tennis player when he was studying for his BA in French and Romance Languages there in the 1960s, made "major contributions to the popularisation of tennis in the USA." Snyder is also a philanthropist—giving generously to his alma mater and other organizations. He co-founded the National Junior Tennis League that reaches 250,000 inner-city young people and constructed a new tennis center at the University of Virginia.
Snyder graduated from The Lawrenceville School in New Jersey and is a 1958 graduate of The University of Virginia with a Bachelor of Arts in French & Romance Languages. At UVa, Snyder was a member of the SPE social fraternity. Snyder received an Honorary Doctorate of Law degree from the University of Dundee in 2002.
Early Business Career
Upon graduation from UVA, Snyder began his career as a Credit Analyst for New York Trust Corporation.
Ed Glassmeyer, Senior Manager of the venture capital firm Oak Partners, funded many of Snyder's early start-up companies, mainly in electronics.:422 Glassmeyer, a Princeton graduate, began in venture capitalism in 1968 to 1970 at CitiCorp Venture Capital. By 1978 he co-founded Oak Investment Partners with Stewart Greenfield and became Managing Partner.
Cambridge Machine Corporation
Snyder's start-up Cambridge Machine Corporation, initiated the development and invention of high-speed mailing/envelope inserting machines. By 1970 Snyder had sold Cambridge Machine Corporation to Pitney-Bowes and he began working for them as National Sales Account manager.:41
In 1971, Snyder founded a start-up packaging company, Instapak, funded by venture capitalist, Ed Glassmeyer. Instapak markets "foam-in-place packaging"—revolutionary for its time— that creates a protective barrier for heavy, fragile instrumentation and computer systems. Instapak is now the largest division of Sealed Air Corporation (NYSE: SEE), with more than 5,500 employees and revenues of $1 billion.
"Sherry we want to develop a biotech company with you, we're all in electronics and we want to see if we can get into biotech and I said Ed you've got the wrong man I don't like science, I haven't been in the science so how could I develop a science based business and he said you know, I know the man you've been able to put markets together and products together and you work with people well and then he said I invest in people I don't invest in technology and so a way it went."— Sherry Snyder interviewed by Fintan Walton for Pharma Television News
In its earliest moments "Genzyme was just really the combination" of Snyder and Henry Blair, a technician at the New England Enzyme Center at Tufts Medical School, who had worked for Roscoe Brady at the National Institute of Health (NIH). According to Snyder, he and Blair "started developing a business on our own." Blair had a contract with the National Institutes of Health (NIH) to produce modified enzymes for the NIH and test it in clinical trials. Roscoe and his colleagues had been working on a treatment for Gaucher's disease for over a decade at that time. Snyder was transformed by the idea that entrepreneurs could "actually help people and save some lives."
Genzyme's first office was an old clothing warehouse adjacent to Tufts Medical School.
By 1983 Genzyme interviewed Baxter employee Henri Termeer, who had completed his MBA at Snyder's alma mater, the University of Virginia in 1973. By that time Genzyme had seventeen employees who worked in an old clothing warehouse adjacent to Tufts Medical School. Genzyme also had a small diagnostics operation in England.
- Bio Information Associates (BIA)
By 1983 Genzyme developed close ties with a group of entrepreneurial professors from MIT and Harvard. These "well-known, full professors who had a lot of multidisciplinary post-docs" had formed a successful Boston-based business management consulting firm a Bio Information Associates (BIA) in 1980. As Termeer described it, "Genzyme was just these professors from MIT and myself and some venture capitalists."
In 1986, Snyder initiated the first sale of Genzyme stock shares (Initial Public Offering).
"In the formative years of biotechnology, Genzyme was the industry’s Apple, blazing a pathway for creating protein-based treatments for rare diseases." Genzyme’s business focused on enzyme deficiency diseases. It first produced diagnostic enzymes for victims of Gaucher's disease, a rare chronic disorder causing enormous enlargement of the spleen, a change in skin pigmentation and bone lesions. It afflicts 10,000 young Hasidic Jews each year. It currently employs 10,000 people worldwide, with approximately $3.6 billion in revenues, with a market valuation of $20 billion. Genzyme (NASDAQ:GENZ) is the largest private employer in Boston, Massachusetts.
Snyder founded Biotage in 1989 which focuses on the development of novel drug development systems. Biotage was acquired by the Swedish biotechnology company Pyrosequencing in 2004 which then took the name Biotage AB.
In 1994 Snyder founded Argonex a small biotech start-up in Charlottesville, VA. In 1996, Snyder founded and served as chairman and chief executive officer of Upstate Biotechnology Incorporated, merging it with Argonex. Upstate Inc. develops innovative cell signaling products, technology platforms and services to accelerate life science research and drug discovery efforts. Upstate was sold to Serologicals Corporation in 2004 for $205 million.
||This article contains content that is written like an advertisement. (August 2010) (Learn how and when to remove this template message)|
||This article appears to contain a large number of buzzwords. (July 2011)|
In 2005 Snyder founded Biocatalyst International, to create financially sustainable biotech firms in partnership with scientists, such as Xcovery, which he co-founded with Dr. Chris Liang, Director of Medicinal Chemistry, Scripps Research Florida, and co-developer of Sutent, Pfizer’s first small molecule oncology drug. Xcovery has 5 lead compounds focused on cancer.
Molecular MD was co-founded with Dr. Brian Druker, inventor of Gleevec, director of the Cancer Center at the Oregon Health Sciences University in Portland. Oregon. Gleevec is a revolutionary small-molecule drug that prevents and stops the growth of cancer cells in chronic myeloid leukemia (CML). MMD is a molecular diagnostic company in the world of personalized medicine utilizing highly sensitive detection systems.
In 2003, he was appointed to Scotland’s International Advisory Board and serves as an advisor to the Scottish government on the development of its biotech sector. In this capacity, Snyder played a major role with the development of an 800,000-square-foot (74,000 m2) bioscience translational center outside Edinburgh.
Board of directors
He is a member of the board of trustees – along with William C. Battle, Arthur Garson Jr, William Black, Sheridan G. Snyder, Patricia J. Edgerton, Aaron Shatkin and Dr. Robert W. Battle – of the Ivy Charitable Foundation, which was created in 2000 and has been a generous benefactor of the University of Virginia's biomedical programs. In 2005 the Ivy Charitable Foundation donated "$45 million to the University of Virginia Health System to expand laboratory space for biomedical research and to speed the translation of new discoveries into effective treatments and cures." This gift was used to construct a new Children's Hospital, the Emily Couric Cancer Center and the Sheridan G. Snyder Translational Research Center.
Snyder funded and developed the National Junior Tennis League (NJTL), along with the encouragement and support of Arthur Ashe and Charles Pasarell. Snyder supported the NJTL for 15 years. This organization now operates, through the USTA, in 110 cities and reaches 250,000 inner-city youths.
In 1988, Snyder was the founder, chairman and CEO of Compuflo Inc., which developed a specialty high-end computer program used to analyze airflow to aid the design of aircraft and autos, a company donated to the University of Virginia to support its laboratories. Snyder also funded University Technology Corporation, where companies were formed with University of Virginia technology and the proceeds generated by these business ventures were donated back to the University.
- Sheridan G. Snyder LLB (hon), OBE, Bloomberg Business, nd, retrieved 17 July 2015
- Joel Kurtzman (25 February 2014). Unleashing the Second American Century: Four Forces for Economic Dominance. PublicAffairs. p. 293. ISBN 9781610393096.
- Fintan Walton (2012), Genzyme: Origin, Growth and business, Boston: PharmaTelevision News Review, BIO
- Marcia Heroux Pounds (9 November 2006), WPB lands headquarters of biotech firm, Palm Beach: Sun Sentinel
- Sir Philip Cohen (2002), Laureation Mr Sheridan Snyder, University of Dundee, retrieved 17 July 2015
- "National Junior Tennis League", University of Virginia, archived from the original on September 22, 2008
- John Frederick Padgett, Walter W. Powell. The Emergence of Organizations and Markets. Princeton University Press.
- Sherry Snyder: Court Reform, New York Magazine, 29 Jun 1970
- Bruce Morgan (April 12, 2012), A Flair for the Business of Medicine: Genzyme founder Henry Blair started his career working as a technician at Tufts medical school, Tufts Now, retrieved July 17, 2015
- Gavin Rynne, Mark Jones, ed. (2013), Conversations with Henri Termeer (PDF), The Life Sciences Foundation Oral History Program, San Francisco, retrieved 7 July 2015 Oral history conducted by Ted Everson, Jennifer Dionisio, Pei Koay, and Arnold Thackray, May 23, December 7, 2006, August 2, 2007, December 18, 2008 & September 30, 2011
- Henri A. Termeer (10 April 2011), Going out on top, Boston Globe, retrieved 17 July 2015 as told to Scott Helman
- Roberts, Edward B.; Eesley, Charles E. (2011). Entrepreneurial impact : the role of MIT--an updated report. Boston, Mass.: Now. p. 58. ISBN 978-1-60198-478-4. Retrieved 21 January 2015.
- "International Advisory Board Members", Scottish Enterprise, archived from the original on August 20, 2007
- Robert Weisman (12 July 2015), How Genzyme became a source of biotech executives, Boston Globe, retrieved 17 July 2015
- "Serologicals Corporation to Acquire Upstate Group", SEC, Atlanta, Georgia and Charlottesville, Virginia, 7 September 2004, retrieved 17 July 2015
- BioCatalyst International, ":Sheridan G. Snyder" http://www.biocatalystintl.com/profile.php?pi=1
- Xcovery - http://www.xcovery.com/
- MolecularMD - http://www.molecularmd.com/
- UVA - http://www.dailypress2.com/forums/showthread.php?p=30471
- http://International Advisory Board - www.scottish-enterprise.com/international-advisory-board-lifesciences
- Ivy Foundation Gives $45 Million to Medicine at U.Va. – Largest Capital Gift Ever to the U.Va. Health System Supports Facilities for Biomedical Research and Patient Care, University of Virginia, 12 December 2005, retrieved 17 July 2015
- Sheridan G. Snyder Translational Research Building - http://www.virginia.edu/vpr/snyder_building.html
- Sheridan Snyder (PDF), Intercollegiate Tennis Association, archived from the original (PDF) on May 20, 2011
- "Sheridan G. Snyder Tennis Center", Virginia Sports, archived from the original on February 16, 2012
- Sheridan Snyder Given ITA Achievement Award, Charlottesville: University of Virginia, 2008, retrieved 17 July 2015